RB1 and prostate carcinoma: Co-deletion of RB1 and RNASEH2B was associated with PARPi resistance in prostate cancer cell lines due in part to E2F1-induced BRCA2 expression, however, inhibition of ATR was able to overcome this resistance via disruption of E2F1-induced BRCA2 expression [103].